India Reduces Prices of 120 Cancer Medicines as 70 Pharma Companies Submit Revised Rates

The Government of India has announced substantial reductions in the maximum retail prices of cancer medicines, with 70 pharmaceutical companies submitting revised prices for 120 anti-cancer drugs under a nationwide initiative to make cancer treatment more affordable. The National Pharmaceutical Pricing Authority (NPPA) has reported price reductions generally ranging from 20% to 70%, with the largest individual reduction reaching 96.45%. The revised prices will become effective across India on November 9, 2026.

The initiative follows the government’s October 17 decision to regulate trade margins on 137 identified non-scheduled anti-cancer medicines, including patented medicines, by limiting them to 30% of the maximum retail price, excluding applicable Goods and Services Tax. According to the Ministry of Chemicals and Fertilizers, the revised prices submitted by pharmaceutical manufacturers cover 1,136 stock-keeping units, representing an important expansion of price regulation for medicines used in cancer treatment.

Price Reductions Expected to Save Patients ₹3,357 Crore

The National Pharmaceutical Pricing Authority estimates that the revised medicine prices could generate savings of approximately ₹3,357.49 crore for patients and the healthcare system. The estimate was calculated by comparing the previous and revised maximum retail prices and applying the difference to sales volumes recorded between April 2025 and March 2026.

The government has clarified that these figures represent estimated savings based on historical medicine consumption rather than expenditure already reduced. Actual savings will depend on the quantities purchased after the revised prices become effective, the medicines prescribed and the extent to which patients previously paid the maximum retail price.

The reported price reductions vary considerably among individual medicines and brands. While pharmaceutical companies have reported reductions generally falling between 20% and 70%, the highest individual reduction of 96.45% demonstrates the scale of the price differences identified in certain products.

Cancer treatment frequently involves repeated administration of expensive medicines over extended periods. Consequently, reductions in medicine prices can make a substantial difference to patients undergoing chemotherapy, immunotherapy, targeted therapy and other specialised treatments.

For families paying directly for treatment, lower medicine prices can help reduce the financial burden associated with repeated hospital visits, diagnostic investigations and prolonged courses of treatment.

Government Regulates Trade Margins on 137 Anti-Cancer Medicines

The National Pharmaceutical Pricing Authority introduced the price rationalisation measure on October 17, 2026, under Paragraph 19 of the Drugs (Prices Control) Order, 2013.

The decision covers 137 non-scheduled anti-cancer medicines identified by an expert committee constituted under the Directorate General of Health Services. The committee included oncologists, medical specialists, representatives of hospitals and government officials who examined the importance of different medicines in cancer treatment.

Unlike scheduled medicines whose prices are regulated through established ceiling-price mechanisms, non-scheduled medicines generally have greater pricing flexibility. The latest intervention addresses excessive trade margins between pharmaceutical manufacturers, distributors, retailers and hospitals.

The government introduced the measure following concerns raised by patients, civil society organisations and state authorities about substantial differences between the prices at which medicines were procured and the maximum retail prices charged to patients.

By limiting trade margins to 30% of the maximum retail price, the NPPA intends to reduce excessive markups while maintaining reasonable commercial margins within pharmaceutical distribution networks.

Important Cancer Medicines Covered by the Pricing Reform

The medicines covered by the trade margin rationalisation programme include treatments used for several forms of cancer, including medicines associated with immunotherapy, targeted therapy and supportive cancer care.

Among the medicines identified by the government are pembrolizumab, durvalumab and osimertinib, which are used in the treatment of specific cancers according to their approved medical indications.

Pembrolizumab and durvalumab belong to a category of medicines known as immune checkpoint inhibitors. These medicines help the immune system recognise and attack certain cancer cells and are used in selected patients with cancers such as lung cancer and other malignancies.

Osimertinib is a targeted therapy used for certain forms of non-small-cell lung cancer involving specific epidermal growth factor receptor mutations. Its inclusion is relevant because targeted cancer medicines can involve substantial expenditure, particularly when patients require prolonged treatment.

The identified medicines also include bevacizumab, used in the management of certain cancers including colorectal and ovarian cancers, and denosumab, which is used for specified bone-related complications associated with cancer.

Pegfilgrastim, a supportive medicine used to reduce the risk of infection associated with chemotherapy-induced neutropenia, is also among the drugs covered by the intervention.

The inclusion of both cancer-directed therapies and supportive medicines reflects the government’s effort to address multiple components of treatment expenditure.

Seventy Pharmaceutical Companies Submit Revised Prices

By November 4, 2026, the NPPA had received revised maximum retail price information from 70 pharmaceutical companies covering 120 of the 137 medicines identified under the programme.

The submissions represent 1,136 stock-keeping units, accounting for different brands, strengths, dosage forms and package configurations marketed by pharmaceutical manufacturers.

The regulatory authority has begun publishing the revised prices on its official website, allowing patients, hospitals, retailers and other stakeholders to consult the updated information.

The price lists are being updated as manufacturers submit additional information. This process provides a mechanism for making revised medicine prices publicly available before implementation begins.

The government has also directed pharmaceutical manufacturers to disseminate the revised prices through newspapers, company websites and communications to hospitals and medicine retailers.

The requirements are intended to ensure that patients and healthcare institutions have access to the updated prices and can identify the applicable maximum retail price for individual formulations.

Revised Prices to Become Effective on November 9

The revised maximum retail prices will become effective from November 9, 2026, and will remain applicable until further orders.

All pharmaceutical manufacturers covered by the notification must calculate revised prices using the prescribed methodology, which is based on their average distributor prices during March 2026.

The calculation excludes medicines supplied free under patient assistance programmes and direct government sales, ensuring that the revised prices are based on the relevant commercial distribution data.

Importantly, manufacturers whose existing medicine prices are already below the newly calculated limits are not permitted to increase those prices to the revised ceiling.

This provision prevents the rationalisation exercise from becoming an opportunity to raise the prices of medicines already being sold at comparatively affordable rates.

Hospitals and retail pharmacies will be required to charge the revised prices from the implementation date. Healthcare institutions must also ensure that the updated prices are communicated and displayed appropriately for patients.

Hospitals and Retail Pharmacies Required to Ensure Compliance

The NPPA has assigned specific responsibilities to pharmaceutical manufacturers, distributors, retail pharmacies and hospitals to support implementation of the new pricing framework.

Manufacturers must submit revised prices to the regulatory authority and communicate them throughout their distribution networks. Hospitals and retailers are expected to ensure that the medicines covered by the notification are sold at prices consistent with the revised maximum retail prices.

The government has placed particular emphasis on hospital pharmacies because substantial quantities of cancer medicines are supplied directly to hospitals and medical institutions.

Patients undergoing cancer treatment frequently obtain specialised medicines through hospital pharmacies, particularly when the medicines require controlled storage, intravenous administration or supervision by medical professionals.

Ensuring that revised prices are reflected in hospital billing systems is therefore an important part of the programme.

State Drug Controllers have been directed to monitor implementation and take appropriate steps to ensure compliance by manufacturers, distributors, retailers and medical institutions.

Pharmaceutical companies are also required to maintain existing production and supply levels for the notified medicines, supporting the continued availability of treatments following the price reductions.

Patients Can Verify Revised Medicine Prices Online

The government has encouraged patients and their families to consult the NPPA website and the official Pharma Sahi Daam platform to verify the revised maximum retail prices of cancer medicines.

The digital platform allows users to search for medicines by brand name, formulation or manufacturer and examine the applicable pricing information.

The NPPA has introduced a dedicated facility for checking revised prices under the Trade Margin Rationalisation programme for anti-cancer medicines.

Patients can use the facility to compare the prices displayed on medicine packaging with the regulatory information published by the authority.

The availability of publicly accessible medicine pricing information is intended to improve transparency and help patients identify instances in which medicines may be sold above the permitted maximum retail price.

It also supports healthcare professionals, pharmacists and hospitals in verifying the updated prices of prescribed medicines.

Building on India’s Earlier Cancer Medicine Pricing Reforms

The latest initiative builds upon an earlier trade margin rationalisation exercise introduced by the NPPA in 2019.

Under that programme, trade margins were regulated for 42 anti-cancer medicines, resulting in price reductions across hundreds of marketed brands.

According to the government, the previous intervention reduced maximum retail prices for 526 brands of non-scheduled anti-cancer medicines, with reductions reaching as high as 90%.

The 2026 programme expands the approach to a substantially larger group of medicines, including newer treatments and patented pharmaceutical products.

The intervention reflects the government’s continuing efforts to improve access to essential medicines by addressing pricing practices within pharmaceutical distribution and retail channels.

Unlike measures that directly regulate manufacturers’ production costs, trade margin rationalisation focuses on limiting the difference between supply-chain prices and the amounts charged to patients.

This approach aims to improve medicine affordability while preserving the legitimate commercial interests of pharmaceutical manufacturers and distributors.

Improving Access to Cancer Treatment in India

Cancer care represents an important and growing component of India’s healthcare requirements. Advances in oncology have introduced new treatment options, including immunotherapies, targeted medicines and specialised supportive therapies that can improve outcomes for selected groups of patients.

However, the cost of these treatments can place considerable financial pressure on households, particularly when medicines must be administered repeatedly over several months.

Reducing the maximum retail prices of commonly prescribed cancer medicines can improve treatment affordability and help patients maintain access to prescribed therapies.

The benefits may extend to families receiving treatment in private hospitals, where medicines and associated medical services can account for a substantial share of treatment expenditure.

Greater price transparency can also help healthcare institutions manage medicine procurement and provide patients with clearer information about treatment expenses.

The new pricing framework complements broader government initiatives intended to improve healthcare affordability, including public health insurance, hospital infrastructure development and access to essential medicines.

A Significant Step Towards Affordable Cancer Care

The submission of revised prices for 120 anti-cancer medicines by 70 pharmaceutical companies marks an important stage in the implementation of India’s latest medicine pricing reform.

With reported price reductions generally ranging from 20% to 70%, the initiative is expected to reduce the financial burden associated with several cancer treatments when the revised prices become effective on November 9.

The government’s estimated savings of ₹3,357.49 crore demonstrate the potential financial significance of regulating excessive trade margins within the pharmaceutical distribution system.

The intervention also establishes stronger requirements for pricing transparency, manufacturer disclosures and compliance by hospitals and retailers.

By extending trade margin rationalisation to a larger group of anti-cancer medicines, including patented therapies, India is strengthening its efforts to make advanced cancer treatment more accessible while maintaining an organised and transparent pharmaceutical pricing framework.

Official References

1. Press Information Bureau, Government of India — 6 November 2026

Cheaper Cancer Medicines: What the New Margin Cap Means for Patients

https://www.pib.gov.in/FactsheetDetails.aspx?ModuleId=16&NoteId=151169&id=151169

2. Ministry of Chemicals and Fertilizers — 17 October 2026

Trade Margin Rationalisation on 137 Anti-Cancer Drugs

https://www.pib.gov.in/PressReleasePage.aspx?PRID=2324743

3. National Pharmaceutical Pricing Authority

Revised Prices of 137 Anti-Cancer Drugs

https://www.nppa.gov.in/en/revised-prices

4. National Pharmaceutical Pricing Authority — Pharma Sahi Daam

Official Medicine Price Verification Portal

https://nppaipdms.gov.in/NPPA/PharmaSahiDaam/searchMedicine